The pre-clinical studyA pre-clinical study in a rodent model of...

The pre-clinical studyA pre-clinical study in a rodent model of pneumonia-induced sepsis was performed under Cynata’s development partnership with RCSI (the Royal College of Surgeons in Ireland), under the leadership of Professor Gerard Curley, Chair of the Department of Anaesthesia and Critical Care at RCSI, and Consultant in Intensive Care Medicine at Beaumont Hospital, Dublin. This partnership was co-funded by Cynata and RCSI under the RCSI Strategic Industry Partnership Seed Fund. In this preclinical model of severe sepsis, Cymerus MSC treatment:

ASX ANNOUNCEMENT 7 September 2020
Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
Melbourne, Australia; 7 September 2020: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the
“Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today
announced positive efficacy data from a study of its induced pluripotent stem cell (iPSC)-derived
Cymerus™ mesenchymal stem cells (MSCs) in a preclinical rodent model of idiopathic pulmonary
fibrosis (IPF).

Only 15 years till all doubt about human approval. Only 5 to 10 years until all doubt is removed about saving the life of a rodent.